Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients: 聚乙二醇洛塞那肽注射液注射联合盐酸二甲双胍有效安全地改善2型糖尿病患者的血糖控制
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: The aim of the present study was to evaluate the efficacy and safety of polyethylene glycol loxenatide (PEX168) injections in Chinese type 2 diabetic (T2D) patients. Methods: The present multicenter randomized double‐blind parallel placebo‐controlled clinical trial enrolled patients who had been treated with a stable dose of metformin (≥1500 mg/day) for ≥12 weeks and had an HbA1c level between 7% and 11%. Subjects were randomly divided into three groups (1: 1: 1) and were treated with once weekly subcutaneous injections of either placebo or 100 or 200 μg PEX168 for 12 weeks. All subjects continued to receive metformin daily. Results: After 12 weeks treatment, the adjusted least‐squares mean of HbA1c reductions from baseline values in the 100 and 200 μg PEX168 groups were significantly higher than in the placebo group (−1.02% [95% confidence interval {CI} –1.33, −0.71), −1.36% [95% CI –1.68, −1.04], and 0.13% [95% CI –0.20, 0.45], respectively; P < 0.05). After treatment, 50% and 60.5% of subjects in the 100 and 200 μg PEX168 groups, respectively, achieved HbA1c levels <7% (P < 0.01 for both vs placebo [HbA1c 11.1%]). The most frequent adverse reactions in the PEX168 groups were mild to moderate dose‐dependent gastrointestinal reactions. There were no reports of hypoglycemia or pancreatitis in any of the groups. Conclusions: Continuous 12 week treatment with PEX168 showed excellent safety and efficacy in T2D patients whose glucose was not well controlled with metformin alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Self-citationDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 4×
“8%, respectively.(13) In the present study, the percentage of patients with HbA1c <7% after treatment in the 100 and 200μg PEX168-treated groups was 50.”
BackgroundMethodInfluentialGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“The association between the molecular weight and spatial structure of long-acting preparations suggests that the ability to pass through the blood–brain barrier may be affected to different degrees.(23) Currently, it is considered that LIRA has the strongest effects on reducing body weight; LIRA links to fatty acids w…”
BackgroundDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Dungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486 · cited 2×
“For example, the AWARD-6 study observed patients for 26weeks.(22) Third, reductions in body weight in response to GLP-1 receptor agonists are achieved through regulation of the feeding center and an increase in satiety.”
ResultLong-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350 · cited 3×
“4 kg.(21) The effect of PEX168 on body weight should be confirmed in further studies using a Figure 6 Changes in homeostatic model assessment of β-cell func-”
BackgroundInfluentialYang, G.-R., Zhao, X.-L., Jin, F., Shi, L.-H., & Yang, J.-K. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.386 · Cited by 29 · cited 2×
“The major adverse reactions reported were anorexia, nausea, vomiting, diarrhea, dizziness, and weakness, with the incidence of these reactions increasing with increasing doses.(10) Once-weekly taspoglutide exhibited greater glycemic control than twice-daily exenatide with comparable weight loss, but all Phase III tria…”
BackgroundSelf-citation
Cited by
Polymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47
Shuai, Y., Yang, G., Zhang, Q., Li, W., Luo, Y., Ma, J., Chen, D., Yang, J., Wang, X., Hu, J., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14198 · Cited by 35
Self-citationPolyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study
Wang, J., Huang, J., Li, W., Tang, S., Sun, J., Zhang, X., Liu, J., Yi, B., Liu, J., Zhang, X., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14091 · Cited by 16
Self-citationZhang, Y., Li, Y., Zhao, J., Wang, C., Deng, B., Zhang, Q., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.781856 · Cited by 15
Self-citation
Metadata
- Authors
- Chen, X., Lv, X., Yang, G., Lu, D., Piao, C., Zhang, X., Jiang, H., Xie, Y., Yang, J., Li, X., Li, Y., Xiao, X., Li, Y., Sun, L., Zheng, S., Cheng, Q., Peng, Y., & Yang, W.
- Venue
- Journal of Diabetes
- Publisher
- Wiley
- Published
- 2016-06-21
- Volume
- 9
- Issue
- 2
- Pages
- 158-167
- ISSN
- 1753-0393 (ISSN-L)
- 1753-0407
- OpenAlex
- W2301888354
- Cited by
- 33
- References
- 8
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients: 聚乙二醇洛塞那肽注射液注射联合盐酸二甲双胍有效安全地改善2型糖尿病患者的血糖控制. https://app.cochat.ai/papers/10.1111/1753-0407.12397
- The paper
- Chen, X., Lv, X., Yang, G., Lu, D., Piao, C., Zhang, X., Jiang, H., Xie, Y., Yang, J., Li, X., Li, Y., Xiao, X., Li, Y., Sun, L., Zheng, S., Cheng, Q., Peng, Y., & Yang, W. (2017). Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients: 聚乙二醇洛塞那肽注射液注射联合盐酸二甲双胍有效安全地改善2型糖尿病患者的血糖控制. Journal of Diabetes. https://doi.org/10.1111/1753-0407.12397
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.